CDKN2/p16 predicts survival in oligodendrogliomas : comparison with astrocytomas

摘要: Cyclin-dependent kinase 4 inhibitor (CDKN2/p16) is a cell cycle regulatory protein that has been demonstrated to be inactivated by mutations, deletions or transcriptional silencing during pathogenesis of variety human malignancies. We studied the correlation CDKN2/p16 expression with proliferation activity and patient survival in 42 oligodendrogliomas 36 astrocytomas. was frequently decreased grade II anaplastic (17/42) where lack predicted poor (p=0.0045). In astrocytomas low associated high histologic malignancy (p=0.002): level 9 out 10 glioblastomas, 5 astrocytomas, 3 none pilocytic astocytomas (0/7). Low also (MIB-1 immunocytochemistry: p=0.004; mitotic index: p=0.007) (p=0.025) mRNA had same topographic distribution as nuclear immunoreactivity proving for reliability immunocytochemical findings. Our results are agreement earlier studies demonstrating inactivation tumorigenesis astrocytic tumors. Furthermore, our findings suggest loss may play an important role progression oligodendrogliomas. According immunocytochemistry could used tool identify those likely progress have outcome, thus would need more aggressive therapy.